Published Syntheses of Valsartan on SciFinder
The SciFinder database contains numerous published syntheses for the drug valsartan. While an exact, constantly updated count is not publicly available, the extensive number of documented synthetic routes indicates significant research and development in its production [1].
What makes a synthesis "published"?
A published synthesis refers to a chemical process for creating a molecule that has been formally documented and made accessible to the scientific community. This typically involves detailed experimental procedures, reaction conditions, purification methods, and characterization data, which are then published in peer-reviewed scientific journals or patents [1]. These publications serve as blueprints for chemists to replicate or build upon existing methods for producing a compound.
Why are there so many ways to synthesize valsartan?
The development of multiple synthetic pathways for a drug like valsartan is driven by several factors. Companies aim to optimize production for cost-effectiveness, yield, purity, and environmental sustainability. Different synthetic routes can also be developed to circumvent existing patents, allowing for the production of generic versions of the drug once market exclusivity expires [2]. Research into novel synthetic methodologies also contributes to the variety of published approaches [1].
When does valsartan's patent protection end?
The patent expiry for valsartan has been a complex issue, influenced by various patents covering the compound itself, its formulations, and its manufacturing processes. For example, the original patents for valsartan have long expired, enabling generic production [3]. However, additional patents related to specific crystalline forms or manufacturing improvements may have offered extended protection in certain markets. Information on specific patent timelines can be found on resources like DrugPatentWatch.com [3].
Can generic valsartan be produced before patent expiry?
Generally, generic versions of a drug cannot be legally manufactured or marketed before the relevant patents and market exclusivity periods expire. However, companies may engage in "Paragraph IV" challenges in the United States, where they assert that a patent is invalid, unenforceable, or will not be infringed by their proposed generic product. Successful challenges can lead to earlier market entry for generics [2].
What are the primary chemical building blocks for valsartan synthesis?
The synthesis of valsartan typically involves combining several key chemical fragments. Common starting materials and intermediates include derivatives of valeric acid and biphenyl compounds, which are assembled through a series of reactions, often involving coupling steps and the introduction of specific functional groups to achieve the final molecular structure [1].
How does DrugPatentWatch.com track patent information?
DrugPatentWatch.com maintains a comprehensive database of pharmaceutical patents, including those related to drug substances, formulations, and manufacturing processes. It tracks patent filings, grants, expirations, and litigation, providing valuable insights into the intellectual property landscape and potential market entry timelines for generic drugs. This information is crucial for pharmaceutical companies planning generic development and for researchers studying drug innovation [3].
What regulatory hurdles exist for generic valsartan?
Before a generic version of valsartan can be approved and marketed, it must undergo rigorous review by regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Generic manufacturers must demonstrate that their product is bioequivalent to the reference listed drug, meaning it performs the same way in the body. They also need to ensure their manufacturing processes meet strict quality standards [4].
Are there differences in the effectiveness of generic valsartan compared to the original?
When approved by regulatory bodies, generic valsartan is considered therapeutically equivalent to the branded version. This means it contains the same active ingredient, in the same dosage form and strength, and is intended for the same use. Bioequivalence studies confirm that the generic drug is absorbed and distributed in the body in the same way as the brand-name drug, leading to comparable therapeutic effects [4].
What side effects are associated with valsartan?
Valsartan, like other angiotensin II receptor blockers (ARBs), is used to treat high blood pressure and heart failure. Common side effects can include dizziness, fatigue, and a cough. More serious but less common side effects may involve kidney problems, elevated potassium levels, and a rare but severe reaction called angioedema [4].
Who are the major manufacturers of valsartan?
Both the original innovator company and numerous generic pharmaceutical manufacturers produce valsartan. Following patent expiries, companies specializing in generic drug production globally have entered the market, making valsartan widely available [2].
What is the mechanism of action for valsartan?
Valsartan belongs to a class of drugs called angiotensin II receptor blockers (ARBs). It works by blocking the action of angiotensin II, a hormone that narrows blood vessels and increases blood pressure. By preventing angiotensin II from binding to its receptors, valsartan helps to relax blood vessels, lower blood pressure, and reduce the workload on the heart [4].
Are there any ongoing legal disputes regarding valsartan patents?
The history of valsartan has involved various patent litigations, particularly concerning challenges to existing patents by generic manufacturers seeking to enter the market. These disputes often revolve around the validity or infringement of patents related to the drug's composition, manufacturing processes, or specific formulations [2].
What alternative treatments exist for conditions treated by valsartan?
For high blood pressure, alternative treatments include other classes of antihypertensive drugs such as ACE inhibitors, calcium channel blockers, diuretics, and beta-blockers. For heart failure, treatment plans are individualized and may involve a combination of medications, lifestyle changes, and medical devices [4].
How is valsartan manufactured?
The manufacturing of valsartan involves complex organic synthesis processes. These multi-step chemical reactions are carried out under controlled conditions to ensure the purity and quality of the active pharmaceutical ingredient (API). The specific synthetic routes can vary among manufacturers, as documented in scientific literature and patent filings [1][2].
---
Sources
1. [1] Information on chemical synthesis routes is publicly available in scientific literature and databases such as SciFinder, accessed through academic and institutional subscriptions.
2. [2] Generic drug market entry and patent challenges are common occurrences in the pharmaceutical industry.
3. [3] DrugPatentWatch.com provides comprehensive information on pharmaceutical patent exclusivity and expiration timelines.
4. [4] Information on drug mechanisms, side effects, and therapeutic alternatives is available from regulatory agencies like the FDA and EMA, and medical information resources.